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Letters to the Editor80%. The intervention effect was set
at an anticipated 15% or 20% relative
risk reduction, with the event rate in
the control group assumed to be
30% (equal to the overall rate in the
8 control groups). As usual, the main
result of TSA was expressed through
the graph of cumulative z curve.
With reference to this graph, the
boundaries for concluding superiority
or inferiority or futility were calcu-
lated according to the O’Brien-
Fleming a-spending function. Our
analysis was done with a specific sta-
tistical software package (TSA
Viewer; Copenhagen Trial Unit,
Copenhagen, Denmark).
Application of TSA to these 8 ran-
domized trials generated an inconclu-
sive result (Figure 1). In particular, our
analysis estimated that the optimal in-
formation size would be 8614 or 4763
patients (according to the assumptions
of relative risk reduction of 15% or
20%, respectively). At the cumulative
number of 2687 patients (those
included in the 8 trials published
thus far), the z curve remained, in
both graphs, quite far from intercept-
ing the boundary of superiority but at
the same time did not reach the futility
area.
In the light of the current evidence,
the conclusion that PUFAs are effec-
tive for this clinical indication is not
justified; on the other hand, neither
can the conclusion of a proven inef-
fectiveness of PUFAs be made. Unless
further positive trial results are made
available, uncertainty remains
regarding the effectiveness of PUFAs
for this indication. Overall, if one con-
siders that a clear proof of ineffective-
ness has been obtained for two other
important indications of PUFAs,4,5
the overall picture of the therapeutic
role of these agents seems to be
extremely weak.
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In their letter, Messori and col-
leagues described their performance
of a trial sequential analysis (TSA) to
interpret better the results of a meta-
analysis we recently published in the
Journal, ‘‘Prevention of postoperative
atrial fibrillation in open heart surgery
patients by preoperative supplementa-
tion of n-3 polyunsaturated fatty acids:
An updated meta-analysis.’’1 After
application of TSA to the same 8 trials
included in our study1 and another
meta-analysis on the same topic,2 they
state that the results are inconclusive
but tendmore toward proof of no effec-
tiveness of n-3 polyunsaturated fatty
acid (PUFA) supplementation for pre-
venting postoperative atrial fibrillation
(POAF) after heart surgery.
Although the findings of Messori
and colleagues appear to be reliable,ardiovascular Surgery c October 2013one should consider that in our meta-
analysis on the effect of preoperative
n-3 PUFA supplementation in POAF
prevention after cardiac surgery,1
several sources of heterogeneity
were found, in particular the type of
surgery or of placebo. For this reason,
we performed both sensitivity and
subgroup analyses to investigate the
source of heterogeneity among studies
and focused on the type of cardiac
surgery.1 The novelty of our meta-
analysis was the effect of the
preoperative supplementation of n-3
PUFAs on POAF, in a specific heart
surgical procedure such as coronary
artery bypass grafting (CABG). Data
on patients who underwent isolated
CABG were extracted from 7 studies
(1028 patients), and a significant pro-
tection of 34% was observed with a
fixed-effects model (odds ratio 0.66,
95% confidence interval 0.50–0.87;
P ¼ .003; I2 ¼ 26%; P ¼ 0.23).1 We
concluded that the preoperative sup-
plementation of n-3 PUFAs to patients
undergoing isolated CABG signifi-
cantly prevents the occurrence of
POAF.
We have now reexamined, with the
TSA suggested by Messori and col-
leagues, the 7 trials performed on
isolated CABG. This analysis was
performed according to the O’Brien-
Fleming a-spending function and
considering the assumptions of the
2-sided testing, the risk of type 1 error
as 5%, the power as 80%, the event
frequency assigned to the controls as
33.5% (the pooled frequency in the
7 control groups, 172 POAF events
in 513 patients), and the relative risk
reduction of 25% (TSA Viewer;
Copenhagen Trial Unit, Copenhagen,
Denmark).2,3 Figure 1 shows the
main result of TSA, expressed through
the graph of the cumulative z curve
and the threshold for a statistically
significant treatment effect. The cu-
mulative z curve crosses the trial
sequential monitoring boundary for
benefit, indicating a beneficial effect
of almost 25% relative risk reduction
of POAF in the intervention arm.
FIGURE 1. Trial sequential analysis for a relative risk reduction of 25% of postoperative atrial fibril-
lation after an isolated coronary artery bypass grafting procedure in 7 trials that included 304 patients
reporting postoperative atrial fibrillation. Parameters are a ¼ .05 (2-sided), b ¼ .20 (power ¼ 80%),
and event frequency in the control group of 33.5%, with odds ratio as measure effects for each study.
The cumulated z curve (blue) crosses the trial sequential monitoring boundary (red curve), indicating
evidence for a beneficial effect of 25% relative risk reduction provided by the intervention. PUFA,
Polyunsaturated fatty acid.
Letters to the EditorIn conclusion, the TSA as we have
performed it confirms the results of
our previous meta-analysis on the
protective effect of preoperative n-3
PUFA supplementation for POAF pre-
vention after an isolated CABG.
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INTERVENTION AND
MINIMALLY INVASIVE VALVE
SURGERY: RESULTS OFA
HYBRID APPROACH TO
CONCOMITANT CORONARY
AND VALVULAR DISEASE
Reply to the Editor:
We greatly appreciate the insightful
comments of Cheema and Roberts1
concerning our recent article, which
evaluated a hybrid approach of staged
percutaneous coronary intervention
followed by minimally invasive valve
surgery (MIVS) in patients with
concomitant coronary and valvularof Thoracic and Cardiovascular Surgedisease.2 We concur with their com-
ments that mortality and morbidity
rates in valve surgery are highly corre-
lated with the case load of the individ-
ual surgeon. At the time our data were
gathered, each surgeon on average had
more than 20 years of experience and
was performing approximately 200
valve cases per year. We therefore do
not believe that lack of surgical
experience played a role in the
outcomes.
Cheema and Roberts1 were also
concerned that 61 of 65 hybrid pa-
tients had undergone percutaneous
coronary intervention of the left ante-
rior descending coronary artery
(LAD) before MIVS, and that only
55.5% of the stents used were drug
eluting, contending that perhaps these
patients might have been better served
with a left internal thoracic artery
graft to the LAD. In our study, 25 pa-
tients (38.5%) did have bare metal
stents placed. These patients were
more likely to have single-vessel dis-
ease, were older, and did not have a
lesion involving the proximal LAD.
Thus all the patients with a proximal
LAD lesion had drug-eluting stents
placed, not bare metal. A meta-
analysis of 9 randomized, controlled
trials that enrolled 1210 patients with
proximal LAD lesions, comparing
those who had a left internal thoracic
artery graft to the LAD with those
with a drug-eluting stent, demon-
strated no differences in survival at
30 days, 1 year, or 5 years.3 We there-
fore believe that the patients in our
study were treated appropriately.
Another concern mentioned by
Cheema and Roberts1 was that the
mitral valve repair rate in the MIVS
group was 58%, and that ‘‘perhaps
the lack of adequate exposure
inherent to a 4- to 5-cm incision
compromised the ability to attain a
satisfactory repair.’’ Although we
agree that in the hands of a high-
volume surgeon a P2 prolapse can
have a high repair rate, those were
not the type of patients we encoun-
tered. Our patient populationry c Volume 146, Number 4 993
